MESUPRON® Met Its Primary Objective Of Demonstrating Efficacy In The Proof Of Concept
 

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) published data last week from its Phase II trial with its oral drug candidate MESUPRON® in first line treatment of patients with HER2-receptor negative metastatic breast cancer...

More...